-
Mashup Score: 0COVID-19 more severe in patients with active acute leukemia, myelodysplastic syndrome - 3 year(s) ago
Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.The findings from the ASH Research Collaborative COVID-19 Registry for Hematology also showed patients with acute myeloid leukemia, acute lymphocytic leukemia
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Link Established Between Active Disease/ICU Deferral and COVID-19 Mortality in AML, ALL, and MDS - 3 year(s) ago
Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators noted that patients with #AML, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with #COVID19 were more likely to experience COVID-19 mortality vs non-cancer patients. #ASH21 | @ASH_hematology @DrPinkalDesai https://t.co/OB4MAmSgjB
-
-
Mashup Score: 1Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS - 3 year(s) ago
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS @DrPinkalDesai @WeillCornell @nyphospital @ASH_hematology #ASH21 #COVID https://t.co/6jFkMgfZa5
-
-
Mashup Score: 5
COVID-19 Takes a Toll on People with Blood Cancers and Disorders
Source: www.hematology.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
2/2 #ASH21 Press Release: COVID-19, 20, 21: Profiling the Latest Risks for Patients with #BloodDisorders in a Time of COVID | Click here to read it now: https://t.co/gDCxxCZRRI https://t.co/Rm7akqcSRb
-
1/2 #ASH21 Press Release: #COVID19, 20, 21: Profiling the Latest Risks for Patients with #BloodDisorders in a Time of COVID | Click here to read it now: https://t.co/gDCxxCZRRI @lauracmichaelis @LisaHicksMD @DrPinkalDesai @felrassi @ASHCollab https://t.co/BMXz2yEkWR
-
-
Mashup Score: 4Program | Clonal Hematopoiesis | AACR Meetings - 3 year(s) ago
Please Note:Â All session times for the AACR Virtual Meeting: Clonal Hematopoiesis are U.S. Eastern Standard Time (EST). Wednesday, August 18, 2021 Session 1: DTA Mutations Session 2: Non-DTA Mutations Thursday, August 19, 2021 Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences Session 4: Population Level Studies of Clonal Hematopoiesis Panel Discussion: Clonal Hematopoiesis: How Do…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Population-Level Studies of Clonal Hematopoiesis: Kirsten Grønbæk @Rigshospitalet, @DrPinkalDesai, and @Jyoti_Nangalia will address this topic in a session during the AACR Virtual Meeting on Clonal Hematopoiesis, August 18-19. Learn more: https://t.co/Uk80FOrx9X #AACRCH21 https://t.co/pKvkKAjQiE
-
-
Mashup Score: 1Program | Clonal Hematopoiesis | AACR Meetings - 3 year(s) ago
Please Note:Â All session times for the AACR Virtual Meeting: Clonal Hematopoiesis are U.S. Eastern Standard Time (EST). Wednesday, August 18, 2021 Session 1: DTA Mutations Session 2: Non-DTA Mutations Thursday, August 19, 2021 Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences Session 4: Population Level Studies of Clonal Hematopoiesis Panel Discussion: Clonal Hematopoiesis: How Do…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Population-Level Studies of Clonal Hematopoiesis: Kirsten Grønbæk @Rigshospitalet, @DrPinkalDesai, and @Jyoti_Nangalia will address this topic in a session during the AACR Virtual Meeting on Clonal Hematopoiesis, August 18-19. Learn more: https://t.co/IRj6MK3ttq #AACRCH21 https://t.co/aN8CuyoNpu
-
-
Mashup Score: 1
PURPOSE Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy. PATIENTS AND METHODS One hundred sixty-three patients with de novo AML (age ≥ 55 years) receiving induction chemotherapy…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Use of Romyelocel-L (myeloid progenitor cells) reduces incidence of infection during induction therapy for AML https://t.co/ilzSHMcw8v #JCO #leusm @DrPinkalDesai https://t.co/T20S1dpBfW
-
-
Mashup Score: 1COVID-19 Update 18: ASH RC COVID-19 Registry for Hematology, Drs. Michaelis, Hicks, Wood, & Desai - 4 year(s) ago
In this installment of our special COVID-19 podcast series, The Hematologist Editor-in-Chief Dr. Laura Michaelis has a conversation with Drs. Lisa Hicks, Bill Wood, and Pinkal Desai. They provide the
Source: SoundCloudCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the latest #TheHematologist podcast, EIC @lauracmichaelis discusses updates of the @ASHCollab #COVID19 Registry w/ @LisaHicksMD, @bwoodmd, & @DrPinkalDesai. Hear Dr. Desai's own experience submitting patient data today! 🎧 💻 📱 Listen now: https://t.co/eY5Am9nKJJ https://t.co/nimzcYCTyi
-
🆕 #COVID19 more severe in patients with active acute leukemia & myelodysplastic syndrome, according to study by @ASH_hematology Research Collaborative COVID-19 Registry for Hematology https://t.co/8h9txl009i #ASH21 presented by @DrPinkalDesai of @WeillCornell @nyphospital